Stock RVTY REVVITY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Revvity, Inc.

Equities

RVTY

US7140461093

Market Closed - Nyse
Other stock markets
 21:00:01 03/05/2024 BST 		5-day change 1st Jan Change
100.6 USD -0.46% Intraday chart for Revvity, Inc. -0.89% -7.96%
04-30 TD Cowen Adjusts Price Target on Revvity to $130 From $123 MT
04-30 JPMorgan Adjusts Price Target on Revvity to $105 From $100, Neutral Rating Maintained MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revvity : Q1 2024 Earnings Transcript
PU
Revvity: Q1 Earnings Snapshot
AQ
Revvity Announces Financial Results for the First Quarter of 2024
BU
Revvity Board Declares Quarterly Dividend
BU
Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings
AQ
Revvity to Present at BofA Securities 2024 Health Care Conference
BU
Revvity Unveils a New Era of Automated Tuberculosis Testing
BU
Revvity Signals Software's New Synergy Solution Redefines Collaboration between Pharma and Contract Partners
AQ
Revvity Signals Software’s New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners
BU
Revvity To Hold Earnings Call on Monday, April 29, 2024
BU
Preliminary Injunction Granted to Enforce Revvity s Rights and Cloud Software Group s Obligations Related to Spotfire Software
AQ
Preliminary Injunction Granted to Enforce Revvity’s Rights and Cloud Software Group’s Obligations Related to Spotfire Software
BU
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
BU
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication
BU
Revvity : Notice of Annual Meeting and Proxy Statement 2024
PU
Revvity to Present at Upcoming Investor Conferences
BU
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions
BU
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023
BU
Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors
BU
Revvity Board Declares Quarterly Dividend
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVTY Stock
  4. News Revvity, Inc.
  5. Press Releases